newsfilter
← Latest News
GlobeNewswire·

Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2

- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company's platform and VLP technology; end-to-end drug product investigation underway - - Data ind